Alison R. Walker

1.5k total citations
61 papers, 613 citations indexed

About

Alison R. Walker is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Alison R. Walker has authored 61 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 20 papers in Molecular Biology and 16 papers in Genetics. Recurrent topics in Alison R. Walker's work include Acute Myeloid Leukemia Research (39 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Multiple Myeloma Research and Treatments (10 papers). Alison R. Walker is often cited by papers focused on Acute Myeloid Leukemia Research (39 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Multiple Myeloma Research and Treatments (10 papers). Alison R. Walker collaborates with scholars based in United States, Germany and Canada. Alison R. Walker's co-authors include William Blum, Rebecca B. Klisovic, Ramiro Garzon, John C. Byrd, Guido Marcucci, Alice S. Mims, Bhavana Bhatnagar, James S. Blachly, Hongyan Wang and Clara D. Bloomfield and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Alison R. Walker

54 papers receiving 604 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison R. Walker United States	14	364	284	125	103	81	61	613
Bijender Kumar United States	11	464 1.3×	268 0.9×	226 1.8×	120 1.2×	94 1.2×	32	748
Friederike Schneider Germany	10	331 0.9×	388 1.4×	114 0.9×	175 1.7×	145 1.8×	16	662
Patricia van den Hoogen Netherlands	8	477 1.3×	329 1.2×	90 0.7×	178 1.7×	26 0.3×	11	734
M Lübbert Germany	9	311 0.9×	218 0.8×	71 0.6×	76 0.7×	75 0.9×	13	605
Michele Gottardi Italy	13	202 0.6×	263 0.9×	57 0.5×	96 0.9×	136 1.7×	37	579
Chozha Vendan Rathinam United States	8	279 0.8×	328 1.2×	129 1.0×	112 1.1×	116 1.4×	16	646
Stéphanie Struski France	16	264 0.7×	171 0.6×	84 0.7×	134 1.3×	112 1.4×	30	596
Shirin Azizidoost Iran	12	256 0.7×	120 0.4×	188 1.5×	83 0.8×	80 1.0×	44	465
Talha Badar United States	14	222 0.6×	390 1.4×	65 0.5×	192 1.9×	161 2.0×	106	642
Iris Appelmann Germany	11	236 0.6×	108 0.4×	48 0.4×	78 0.8×	70 0.9×	22	438

Countries citing papers authored by Alison R. Walker

Since Specialization

Citations

This map shows the geographic impact of Alison R. Walker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison R. Walker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison R. Walker more than expected).

Fields of papers citing papers by Alison R. Walker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison R. Walker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison R. Walker. The network helps show where Alison R. Walker may publish in the future.

Co-authorship network of co-authors of Alison R. Walker

This figure shows the co-authorship network connecting the top 25 collaborators of Alison R. Walker. A scholar is included among the top collaborators of Alison R. Walker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison R. Walker. Alison R. Walker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lancet, Jeffrey E., Rami S. Komrokji, Javier Pinilla‐Ibarz, et al.. (2024). Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting. Blood. 144(Supplement 1). 2820–2820.

Komrokji, Rami S., Najla H. Al Ali, Zhuoer Xie, et al.. (2024). IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD). Blood. 144(Supplement 1). 3228–3228.

Zahra, Fatima Tuz, Onyee Chan, Jeffrey E. Lancet, et al.. (2024). Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience. Blood. 144(Supplement 1). 2415–2415. 1 indexed citations

Chan, Onyee, Kendra Sweet, Somedeb Ball, et al.. (2024). A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia. Blood. 144(Supplement 1). 1520–1520. 3 indexed citations

Chan, Onyee, Luis E. Aguirre, Mary Burke, et al.. (2023). Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax. Blood. 142(Supplement 1). 5935–5935. 1 indexed citations

Aguirre, Luis E., Akriti Jain, Somedeb Ball, et al.. (2023). Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models.. Journal of Clinical Oncology. 41(16_suppl). 7020–7020.

El‐Jawahri, Areej, Alison R. Walker, Deborah Russell, et al.. (2022). Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Journal of Adolescent and Young Adult Oncology. 12(4). 592–598. 4 indexed citations

Walker, Alison R., John C. Byrd, James S. Blachly, et al.. (2020). Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression. Clinical Cancer Research. 26(22). 5852–5859. 27 indexed citations

Huang, Ying, James S. Blachly, Nicole R. Grieselhuber, et al.. (2020). The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent. Clinical Lymphoma Myeloma & Leukemia. 21(1). e76–e83. 4 indexed citations

10.

Cremer, Anjali, Jana M. Ellegast, Gabriela Alexe, et al.. (2019). Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. Cancer Discovery. 10(2). 214–231. 26 indexed citations

11.

Zhao, Qiuhong, Daelynn R. Buelow, Mitch A. Phelps, et al.. (2019). Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Investigational New Drugs. 38(2). 340–349. 32 indexed citations

12.

DeAngelo, Daniel J., Alison R. Walker, Richard F. Schlenk, et al.. (2019). Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research. 85. 106197–106197. 16 indexed citations

13.

Roddy, Julianna, et al.. (2017). A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine. Journal of Oncology Pharmacy Practice. 24(4). 290–298. 11 indexed citations

14.

Walker, Alison R., Hongyan Wang, Katherine Walsh, et al.. (2016). Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. Leukemia & lymphoma. 57(9). 2100–2108. 37 indexed citations

15.

Vaughn, John L., David Kline, Nathan Denlinger, Leslie A. Andritsos, & Alison R. Walker. (2016). Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy. Blood. 128(22). 2413–2413. 2 indexed citations

16.

Walker, Alison R. & Guido Marcucci. (2014). Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers. Journal of the National Comprehensive Cancer Network. 12(4). 527–534. 3 indexed citations

17.

Huang, Xiaomeng, Sebastian Schwind, Bo Yu, et al.. (2013). Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clinical Cancer Research. 19(9). 2355–2367. 151 indexed citations

18.

Walker, Alison R., Rebecca B. Klisovic, Jeffrey S. Johnston, et al.. (2012). Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 54(9). 1996–2002. 24 indexed citations

19.

Walker, Alison R., et al.. (2008). Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma. Cancer Investigation. 26(4). 431–433. 31 indexed citations

20.

Walker, Alison R., Rami S. Komrokji, Jainulabdeen J. Ifthikharuddin, et al.. (2008). Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leukemia Research. 32(12). 1830–1836. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact